Immunoglobulin News and Research

RSS

Study predicts good passive immunotherapy donors to combat COVID-19

A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.

19 Jan 2021

Study sheds light on the causes of debilitating gut pain

A new study, published in the journal Nature, reports evidence from mice and humans that a novel mechanism contributes to chronic gut pain.

17 Jan 2021

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

An encouraging new study describes a promising new therapeutic antibody that shows potent neutralizing activity against SARS-CoV-2, the causative agent of COVID-19.

15 Jan 2021

Study shows why antihistamine drugs fail to control severe itch in eczema patients

In addition to a skin rash, many eczema sufferers also experience chronic itching, but sometimes that itching can become torturous. Worse, antihistamines -- the standard treatment for itching and allergy -- often don't help.

15 Jan 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.

12 Jan 2021

Sustained immune response memory detected in recovered COVID-19 patients

A team of researchers at the University of Washington School of Medicine has found that people who had mild COVID-19 developed a multi-layered immune response against SARS-Cov-2. The researchers detected neutralizing antibodies against the virus for at least three months after recovering from the infection.

11 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

As the world struggles to contain the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for over 1.6 million deaths and 76 million infections globally, researchers are trying to pin down the determinants of lethality, of infectivity and of protection. Such data would help contain its spread and develop preventive and therapeutic antivirals and vaccines. A new preprint that appeared recently on the bioRxiv* server describes the high degree of protection afforded by antibodies that target the N-terminal domain (NTD) of the virus.

24 Dec 2020

Higher BMI linked to increased risk of SARS-CoV-2 infection

Researchers at the University of Miami Miller School of Medicine, USA, revealed that the spike-specific immunoglobulin G antibodies in obese people are negatively associated with body mass index (BMI) and serum levels of proinflammatory and metabolic markers of pulmonary inflammation.

24 Dec 2020

Abbott gets CE Mark for new quantitative SARS-CoV-2 IgG lab-based serology test

Abbott announced today it received CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology test.

18 Dec 2020

Researchers test commercial assays to detect SARS-CoV-2 antibodies six months after infection

Researchers at the Hospices Civils de Lyon (HCL) in France found that people infected with SARS-CoV-2 can develop antibodies that persist for up to six months. After testing commercial assays to detect antibodies, the Wantai antibody assay has a positivity rate of 100%.

14 Dec 2020

Case study suggests kindergartens are not SARS-CoV-2 super-spreaders

A new study by researchers at the Institute of Tropical Medicine and International Health at the Charite Universitaetsmedizin Berlin found that kindergartens are not silent transmission reservoirs.

11 Dec 2020

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

A recent study by US researchers, currently available on the medRxiv preprint server, evaluated several cell-based assays that are under validation for determining correlates of protection in individuals with symptomatic coronavirus disease (COVID-19) and vaccine studies – and demonstrated their high concordance with both live and pseudotyped virions.

9 Dec 2020

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

A new study published on the preprint server bioRxiv in December 2020 indicates the ability of anti-SARS-CoV-2 antibody titers and time of induction to differentiate between severe and mild COVID-19 and could lead to the development of a prognostic biomarker for use early in the course of the illness.

8 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Designed proteins assemble antibodies into modular nanocages

With cues from nature, designing functional molecules enables scientists to nanoengineer and customize for specific uses.

3 Dec 2020

Novel “multitope” vaccine shows promise in the fight against COVID-19

Researchers have demonstrated the potential of a protein-peptide vaccine to protect against infection with SARS-CoV-2, the agent that causes COVID-19.